文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

超局灶挽救性高剂量率近距离放疗治疗放射性复发前列腺癌的安全性:150例患者毒性评估

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-12-11

本研究基于前瞻性登记数据,评估150例放射性复发前列腺癌患者接受超局灶挽救性高剂量率近距离放疗(HDR-BT)后的治疗相关毒性。处方为单次19 Gy照射多参数MRI和PET-CT识别的复发灶。中位随访20个月,新发2级和3级毒性分别为泌尿生殖(GU)41%和3%、胃肠道(GI)5%和0%、勃起功能障碍(ED)22%和15%。基线GU毒性≥2级、基线ED≥2级、IPSS≥14和尿道剂量D10%≥17 Gy是≥2级毒性的显著危险因素。

要点

  • 超局灶挽救性HDR-BT单次19 Gy是安全的再治疗方案。
  • 基线症状良好的患者尤其适合该治疗。
  • 遵守尿道剂量约束对避免GU毒性重要。

核心结论

  • 超局灶挽救性HDR-BT是安全的再治疗选择,尤其适用于基线症状良好的患者。
  • 遵守尿道剂量约束对避免GU毒性很重要。

研究设计与样本

  • 治疗目标为单次19 Gy照射多参数MRI和PET-CT识别的复发灶。
  • treating physicians按CTCAE 4.0在基线和随访时分級GU、GI毒性和ED。
  • 对新发≥2级毒性≥10%的领域采用混合效应逻辑回归分析潜在危险因素。

主要发现

  • 中位随访20个月(IQR 12-31)。
  • 新发2级和3级毒性:GU 41%和3%,GI 5%和0%,ED 22%和15%。
  • GI毒性保持稳定低水平,而≥2级GU毒性和ED在晚期(治疗3个月后)频率翻倍。
  • ≥2级毒性的显著危险因素包括基线GU毒性≥2级、基线ED≥2级、IPSS≥14和尿道剂量D10%≥17 Gy。

关键数值与推荐

  • 治疗处方:单次19 Gy照射复发灶。
  • ≥2级毒性显著危险因素:基线GU毒性≥2级、基线ED≥2级、IPSS≥14、尿道剂量D10%≥17 Gy。
  • 新发2级和3级毒性:GU 41%和3%,GI 5%和0%,ED 22%和15%。

临床怎么用

  • 超局灶挽救性HDR-BT可用于放射性复发前列腺癌的再治疗。
  • 治疗前评估基线GU毒性、ED和IPSS,选择症状良好的患者。
  • 治疗计划中应遵守尿道剂量约束(如D10%<17 Gy)以减少GU毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Local re-treatment of radiorecurrent prostate cancer is potentially curative. However, the increased risk of severe toxicity may outweigh the opportunity of cancer control. This study aims to evaluate treatment-related toxicity from ultrafocal salvage high-dose-rate brachytherapy (HDR-BT) and to investigate potential risk factors. MATERIALS AND METHODS: Toxicity data from 150 treated patients (July 2013-November 2019) was collected from a prospective registry. The treatment aim was to deliver a single dose of 19 Gy to the recurrent lesion as identified on multiparametric MRI and PET-CT. Treating physicians graded genitourinary (GU) and gastro-intestinal (GI) toxicity and erectile dysfunction (ED) using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0, at baseline and during follow-up. Domains with substantial (≥10%) new-onset grade ≥ 2 toxicity were further evaluated using mixed effects logistic regression to find potential risk factors. RESULTS: Median follow-up time was 20 months (IQR 12-31). Over time, new-onset grade 2 and 3 toxicity was recorded in 41% and 3% (GU), 5% and 0% (GI) and 22% and 15% (ED). While GI toxicity remained stably low, grade ≥ 2 GU toxicity and ED were seen twice as frequent in the late phase (>3 months after treatment). Significant risk factors for grade ≥ 2 toxicity were baseline GU toxicity (grade ≥ 2), baseline ED (grade ≥ 2), IPSS (cut-off ≥ 14) and urethral dose (D10%, cut-off ≥ 17 Gy). CONCLUSION: Ultrafocal salvage HDR-BT is a safe re-treatment option, especially in patients with a favorable symptom profile at baseline. Adherence to urethral dose constraints is important to avoid GU toxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. van Son M, Peters M, Moerland M, et al. Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients. Clin Transl Radiat Oncol. 2020. PMID: 33364450. doi:10.1016/j.ctro.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。